Entero Therapeutics, Inc. (NASDAQ:ENTO) Sees Significant Drop in Short Interest

Entero Therapeutics, Inc. (NASDAQ:ENTO) was the recipient of a significant drop in short interest during the month of February. As of February 28th, there was short interest totalling 96,000 shares, a drop of 31.3% from the February 13th total of 139,800 shares. Based on an average daily volume of 309,400 shares, the short-interest ratio is presently 0.3 days. Currently, 2.1% of the company’s shares are short sold.

Entero Therapeutics Stock Performance

Entero Therapeutics stock opened at $0.48 on Friday. Entero Therapeutics has a 12-month low of $0.19 and a 12-month high of $3.16. The company has a 50-day moving average price of $0.53 and a 200 day moving average price of $0.52.

Entero Therapeutics Company Profile

Entero Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of targeted and orally delivered therapies for the treatment of patients with gastrointestinal diseases. The company's pipeline candidates include latiglutenase, a targeted oral biotherapeutic for celiac disease designed to breakdown gluten into non-immunogenic peptides, currently under Phase 2 studies; and capeserod, a selective 5-HT4 receptor partial agonist under Phase 1 studies for the treatment of gastroparesis.